A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

Cell and gene therapy (CGT) represents the pinnacle of biomedical innovation, offering unprecedented potential to treat, ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

One of the key advantages of CAR T-cell therapy is that it does not cause the side-effects associated with chemotherapy and ...